To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 January 2025 to Question 21831 on Cancer: Drugs, if his Department will make an assessment of the potential implications for his policies of the findings on page 21 of the European Federation of Pharmaceutical Industries and Associations’ publication entitled EFPIA Patients W.A.I.T. Indicator 2023 Survey, published in June 2024, that 25% of new oncology medicines approved by the European Medicines Agency had full public availability to English patients in 2019-2022.
The Government wants National Health Service patients to benefit from effective NHS treatments at a price that is fair to the NHS and the taxpayer. It is important that we have a system in place for making evidence-based decisions on whether new medicines...
Cancer: Drugs